Technology Bundle ID: TAB-2647

Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception

Request More Info
Licensing Contact:
Primary Inventors: 
Xianfu Wu (CDC)
Co-Inventors: 
Charles Rupprecht (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 
CDC

This invention relates to a recombinant, attenuated rabies vaccine that is also capable of inhibiting reproductive fertility. An Evelyn-Rokitnicki-Abelseth (ERA) rabies vaccine backbone, combined with a reproductive-specific protein, such as gonadotropin-releasing hormone (GnRH) or the sperm-binding zona-pellucida-glycoprotein-3 (ZP3) receptor, allows reduction in both rabies transmission and uncontrolled reproduction in stray animals. The ERA rabies vaccine backbone has previously shown strong efficacy in animal studies. This vaccine may be delivered via injection or orally, including in an animal's food.

Applications:
  • Development of rabies and immunocontraceptive vaccines
  • Immunogenic compositions for both prevention and treatment of rabies virus
  • Animal welfare initiatives and rabies vaccination programs
Advantages:
  • Live, attenuated rabies vaccines show greater efficacy than older, inactivated rabies vaccine in prior animal studies
  • Potential for oral delivery, enabling vaccination of feral and difficult-to-reach animal populations
  • Novel approach to simultaneously addressing rabies transmission and uncontrolled wild animal reproduction

Patents

PCT Application PCT/US2009/054502
Filed on 2009-08-20
US Application 61/097,748
Filed on 2008-09-17
US Pat 8,524,247

Issued 2013-09-03

Publications

Wu X, et al.
PMID 19925954

Updated

Sep 19, 2013

Data Source: 
tts